Climb Bio, Inc. — fact timeline

Climb Bio, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $100.0 million in aggregate offering price (effective 2026-06-12).

“On June 12, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Common Stock”), from time to time through Jefferies.”

Climb Bio, Inc. shareholders approved Approval of the 2021 Plan Amendment.

“4. The stockholders of the Company approved the 2021 Plan Amendment. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Against Abstentions Broker Non- Votes 19,604,493 7,810,582 16,229 7,841,185”

Climb Bio, Inc. shareholders rejected Amendment to the Amended and Restated Certificate of Incorporation relating to the removal of directors for cause.

“3. The stockholders of the Company did not approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, relating to the removal of directors for “cause”. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Against Abstentions Broker Non- Votes 27,299,535 130,187 1,582 7,841,185”

Climb Bio, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 at the 2026-12-31 meeting.

“2. The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Against Abstentions 35,206,304 63,633 2,552”

Climb Bio, Inc. shareholders approved Election of Alexander (Bo) Cumbo and Douglas Williams, Ph.D. to the Board of Directors.

“1. The stockholders of the Company elected Alexander (Bo) Cumbo and Douglas Williams, Ph.D., to the Company’s Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Withheld Broker Non- Votes Alexander (Bo) Cumbo 26,035,689 1,395,615 7,841,185 Douglas Williams, Ph.D. 24,505,866 2,924,838 7,841,185”

Climb Bio, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 7, 2026, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Climb Bio, Inc. issued pre-funded warrants to purchase 2,106,000 shares of warrant to certain institutional accredited investors, including an affiliate of RA Capital Management for $9.4999 per Pre-Funded Warrant.

“to certain Investors in lieu of Shares, pre-funded warrants to purchase 2,106,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $9.4999 per Pre-Funded Warrant”

Climb Bio, Inc. issued 9,481,000 shares of common stock to certain institutional accredited investors, including an affiliate of RA Capital Management for $9.50 per Share.

“the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $9.50 per Share”

Climb Bio, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors, including an affiliate of RA Capital Management valued at approximately $110.0 million (effective 2026-04-27).

“On April 27, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), including an affiliate of RA Capital Management (“RA Capital”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock”

Climb Bio, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.

“Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.”

Climb Bio, Inc. entered into Exchange Agreement with RA Capital Management, L.P. and an entity affiliated with RA Capital (effective 2025-12-11).

“On December 11, 2025, Climb Bio, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with RA Capital Management, L.P. (“RA Capital”) and an entity affiliated with RA Capital (the “Exchanging Stockholder”), pursuant to which the Exchanging Stockholder agreed to exchange (the “Exchange”) an aggregate of 20,440,000 shares of the Company’s common stock”

Cindy Driscoll was appointed as Senior Vice President, Finance at Climb Bio, Inc..

“The Board of Directors (the “Board”) of Climb Bio, Inc. (the “Company”) appointed Cindy Driscoll as Senior Vice President, Finance of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective as of June 17, 2025”

Aoife Brennan was appointed as interim principal financial officer at Climb Bio, Inc..

“On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.”

Brett Kaplan departed as Chief Operating Officer and principal financial officer at Climb Bio, Inc..

“On May 23, 2025, Climb Bio, Inc. (the “Company”) and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr. Kaplan would separate from the Company, effective May 23, 2025”

Kimberlee (Kim) Drapkin was elected as member of the board of directors at Climb Bio, Inc..

“Ms. Drapkin was elected to serve with a term expiring at the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly appointed and qualified or until her earlier death, resignation or removal.”

Alexander (Bo) Cumbo was elected as member of the board of directors at Climb Bio, Inc..

“Mr. Cumbo was elected to serve with a term expiring at the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been duly appointed and qualified or until his earlier death, resignation or removal.”

Adam Rosenberg departed as member of the board of directors at Climb Bio, Inc..

“Adam Rosenberg notified the Company that he does not intend to seek re-election as a member of the Board when his current term ends at the Company’s 2025 annual meeting of stockholders.”

Simon Tate resigned as member of the board of directors at Climb Bio, Inc..

“Simon Tate notified Climb Bio, Inc. (the “Company”) of his decision to resign as a member of the Company’s board of directors”

Climb Bio, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2024-10-02).

“the Board also approved an amendment and restatement of the Company’s Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “Amended and Restated Bylaws”) effective as of October 2, 2024.”

Climb Bio, Inc.: Amended certificate of incorporation to change company name from Eliem Therapeutics, Inc. to Climb Bio, Inc (effective 2024-10-02).

“Effective as of 4:00 p.m., Eastern Time on October 2, 2024, Eliem Therapeutics, Inc. (the “Company”) amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), to effect a change of the Company’s name from “Eliem Therapeutics, Inc.” to “Climb Bio, Inc.””

Andrew Levin was appointed as Chairman of the Board at Climb Bio, Inc..

“The appointment was made in connection with Andrew Levin’s resignation from his role as Executive Chairman of the Company. Dr. Levin continues to serve as a director of the Company and was appointed Chairman of the Board in connection with his resignation as Executive Chairman.”

Brett Kaplan was appointed as principal financial officer at Climb Bio, Inc..

“On August 26, 2024, the Board of Directors of the Company (the “Board”) appointed Brett Kaplan, the Company’s Chief Operating Officer, to serve as principal financial officer.”

Brett Kaplan, M.D. was appointed as Chief Operating Officer at Climb Bio, Inc..

“On August 26, 2024, Eliem Therapeutics, Inc. (the “Company”) announced that its board of directors (the “Board”) had appointed Brett Kaplan, M.D., as Chief Operating Officer of the Company, effective August 26, 2024”

Climb Bio, Inc. completed an acquisition involving Tenet Medicines, Inc. (closed 2024-06-27).

“On June 27, 2024, the Company completed its acquisition of Tenet in accordance with the terms of the Acquisition Agreement.”

Stephen Thomas was elected as Director at Climb Bio, Inc..

“the Board elected Stephen Thomas, Ph.D., the then-Chief Executive Officer of Tenet, to serve as a director on the Board, subject to and contingent and effective upon the closing of the Acquisition, from the Effective Date until the Company’s 2025 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”

Aoife Brennan was elected as Director at Climb Bio, Inc..

“In addition, Dr. Brennan was elected as a director to serve on the Board from the Effective Date until the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal.”

Aoife Brennan was appointed as President and Chief Executive Officer at Climb Bio, Inc..

“the Company’s Board of Directors (the “Board”) appointed Aoife Brennan, M.B., Ch.B., as President and Chief Executive Officer of the Company, effective upon the closing of the Acquisition (the “Effective Date”).”

Aoife Brennan was appointed as President and Chief Executive Officer at Climb Bio, Inc..

“appointed Aoife Brennan as President and Chief Executive Officer of Eliem, subject to and contingent and effective upon the closing of the Acquisition”

Climb Bio, Inc. entered into Securities Purchase Agreement with several accredited institutional investors valued at 31,238,282 shares of the Company’s common stock ... at a price of $3.84 per PIPE Share (effective 2024-04-10).

“On April 10, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several accredited institutional investors (the “PIPE Investors”), pursuant to which the Company agreed to issue and sell to the PIPE Investors in a private placement an aggregate of 31,238,282 shares of the Company’s common stock (the “PIPE Shares”), at a price of $3.84 per PIPE Share (the “Private Placement”).”

Climb Bio, Inc. entered into Agreement and Plan of Merger and Reorganization with Tenet Medicines, Inc. (effective 2024-04-10).

“On April 10, 2024, Eliem Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Acquisition Agreement”) by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Transitory Subsidiary”), Tenet Medicines, Inc., a Delaware corporation (“Tenet”), and, solely in his capacity as company equityholder representative, Stephen Thomas.”

Climb Bio, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-18 meeting.

“Stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”

Climb Bio, Inc. shareholders approved Election of Class II director to serve until 2026 Annual Meeting at the 2023-05-18 meeting.

“Stockholders elected the nominee for Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified.”

Climb Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $22.3 million.

“Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.”

Emily Pimblett was appointed as principal accounting officer at Climb Bio, Inc..

“and (ii) Emily Pimblett, Chief Accounting Officer, as the Company’s principal accounting officer.”

Andrew Levin was appointed as principal financial officer at Climb Bio, Inc..

“Effective as of March 10, 2023 (the “Transition Date”), the Board appointed (i) Andrew Levin, Executive Chairman, as the Company’s new principal financial officer (in addition to principal executive officer)”

Erin Lavelle resigned as Executive Vice President, Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc..

“the Company and Erin Lavelle mutually agreed that Ms. Lavelle would resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company.”

Climb Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss was $7.8 million for the three months ended December 31, 2022, and $45.2 million for the full year 2022.

“On March 6, 2023, Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.”

Climb Bio, Inc. announced a restructuring with charges of approximately $17.1 million (approximately 55%).

“program. As part of the Plan, the Company will reduce its workforce by approximately 55% in the first half of 2023. The Company estimates that it will incur approximately $17.1 million in charges in connection with the Plan, which will be substantially incurred in 2023. These charges primarily relate to employee transition, severance payments, employee”

Andrew Levin changed role as Executive Chairman at Climb Bio, Inc..

“On February 13, 2023, in connection with the departure of Mr. Azelby, Andrew Levin assumed the role of Executive Chairman and will act as the Company’s principal executive officer on an interim basis while the Company conducts a search for a permanent Chief Executive Officer.”

James Bucher resigned as Executive Vice President and General Counsel at Climb Bio, Inc..

“Eliem entered into a letter agreement with three of its executive officers – President, Chief Executive Officer and Director Robert Azelby, Executive Vice President, Chief Operating Officer and Chief Financial Officer Erin Lavelle, and Executive Vice President and General Counsel James Bucher (each, an “Officer”) – pursuant to which each such Officer will resign from his or her positions with the Company.”

Erin Lavelle resigned as Executive Vice President, Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc..

“The Company and Ms. Lavelle mutually agreed that Ms. Lavelle will resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company.”

Robert Azelby resigned as President and Chief Executive Officer at Climb Bio, Inc..

“The Company and Mr. Azelby mutually agreed that Mr. Azelby will resign as President, Chief Executive Officer and as a member of the Board.”

Leone Patterson resigned as Director at Climb Bio, Inc..

“On January 19, 2023, Leone Patterson notified Eliem Therapeutics, Inc. (Eliem, or the Company) of her decision to resign from the Board of Directors of the Company (the Board), effective immediately.”

Climb Bio, Inc. reported the quarter ended September 30, 2022 results: net income $9.7 million.

“Net loss was $9.7 million for the three months ended September 30, 2022, compared to $9.6 million for the same period in 2021.”